Opinion|Videos|September 17, 2024
Innovations and Future Directions in Higher Risk MDS Treatments
Medical experts discuss innovations and future directions in treatments for higher-risk MDS.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the key challenges in developing effective therapies for patients with TP53-mutated higher-risk myelodysplastic syndromes (MDS), and what strategies are being explored to address these challenges?
- What innovations in the pipeline for higher-risk MDS treatments are you most excited about? What role do you think novel targeted therapies and/or combination therapy will have in future MDS treatment paradigms?
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol
2
SYNCHRONIZE-1 Through a Hepatologist's Lens: Liver Fat Reduction, Visceral Fat, and What Comes Next
3
AI Phenotyping Links Cardiovascular, Kidney Disease to Rapid MASH Progression, Higher Costs
4
Stem Cell Transplant Outperforms DMTs in Drug-Resistant Relapsing MS
5